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Summary 
 
This case report describes a 5-year-old pregnant Warmblood mare which was being treated for 
fibrinous bacterial pleuropneumonia. Since initial attempts to drain and lavage both pleural 
cavities were ineffective due to the presence of extensive intrapleural fibrin loculations, 
recombinant human tissue plasminogen activator (tPA) was instilled into both pleural cavities, 
to promote fibrinolysis and improve drainage. Within 1-2 h of instilling tPA, the horse became 
distressed, with increasing dyspnoea, tachycardia, pleurodynia and hypoxaemia. At 4 h post 
tPA instillation, diffuse bilateral pulmonary oedema was evidenced by the onset of widespread 
audible inspiratory crackles and ultrasonographic ring-down artefacts. Ultrasonography 
demonstrated that tPA had induced pleural fibrinolysis, thereby removing the restrictive effects 
of pleural adhesions on lung motion and facilitating lung re-expansion. Re-expansion 
pulmonary oedema (RPE) was suspected, although an adverse drug reaction could not be 
excluded. The complication resolved with nasal oxygen supplementation, and administration 
of frusemide, meloxicam, morphine and hydroxyethyl starch. Subsequent repetition of 
intrapleural tPA instillation and thoracic drainage had no apparent adverse effect. The mare 
was discharged from the hospital and subsequently foaled successfully. The pathogenesis, 
diagnosis and management of RPE is reviewed. 
  
Introduction 
RPE is a potentially fatal iatrogenic complication of rapid lung re-expansion following 
thoracocentesis for the treatment of pneumothorax or pleural effusion. RPE has an incidence 
of 0.9-32.5% and a mortality rate of 1.2-20% in human patients undergoing thoracic drainage 
(Mahfood et al. 1988; Kim et al. 2009; Taira et al. 2014). While RPE is proposed as one of the 
mechanisms contributing to equine post-anaesthetic pulmonary oedema (Ball and Trim 1996; 
Kaartinen et al. 2010), it has not been reported following equine pleural drainage. Given that 
human RPE may be under-diagnosed when mild or asymptomatic, and when post procedure 
imaging is not performed (Feller-Kopman et al. 2007; Taira et al. 2014), RPE may also be 
under-diagnosed in horses. This report describes the successful treatment of a case of suspected 
RPE in a horse which developed following intrapleural tPA instillation for management of 
fibrinous pleuropneumonia. Brief details of this case were included in a review of 25 horses 
which had received tPA for the treatment of fibrinous pleuropneumonia (Tomlinson et al., 
2015).  
 
Case details 
Case history 
A 5-year-old, 567 kg body weight, 4 month-pregnant, Warmblood mare presented to Dick Vet 
Equine Hospital with fibrinous bacterial pleuropneumonia following long distance 
transportation 6 days previously.  
Clinical examination  
The mare had pyrexia (39.3oC), tachycardia (65 beats/min), tachypnea (32 breaths/min), 
shallow breathing pattern with increased inspiratory effort, elevated jugular pulse and a grade 
1-2/6 left sided early systolic murmur presumed to be a flow murmur. Normal breath sounds 
were audible over both dorsal hemithoraces but were absent over both ventral hemithoraces. 
No crackles were audible.  
Diagnosis and treatment 
Ultrasonography revealed bilateral pleural effusion, marked organising fibrin pleural adhesions 
and loculations and collapse of ventral lung regions (Supplementary Video File 1). Pleural fluid 
extended to a level approximately 56% up an imaginary transect from the ventral to dorsal 
pleural reflections, at a level immediately caudal to the forelimbs, bilaterally. Lung motion 
during the breath cycle was severely restricted. Ultrasonographic ring-down artefacts were not 
evident at this stage. Streptococcus zooepidemicus and Chryseomonas indologenes were 
cultured from pleural fluid and tracheal aspirate, respectively. Cefquinome, gentamicin, 
metronidazole, flunixin, meloxicam and intravenous crystalloid fluid therapy were 
administered at various time points during the hospitalisation period. The mare’s clinical 
parameters remained fairly stable for the first 3 days of hospitalisation. Attempted pleural 
drainage and lavage (5-10 L Hartmann’s solution) via bilateral indwelling thoracic drains daily 
for 3 days was ineffective because of extensive fibrin loculations. Total net volumes of pleural 
fluid obtained over the first 3 days were only 13 L and 6 L from the left and right pleural 
cavities, respectively. Immediately after the third attempt to drain the pleural cavities, to 
promote fibrinolysis and facilitate more effective drainage, recombinant human tissue 
plasminogen activator (tPA; 12.5 mg in 1L 0.9% NaCl) was instilled into each pleural cavity, 
and the drains clamped, with a view to repeating thoracic drainage and lavage 12-24 h later. 
However, within 1-2 h following this procedure, the mare became agitated and increasingly 
dyspnoeic. Breathing and heart rates increased to 60/min and 110/min, respectively. Breathing 
pattern changed from shallow to deep, with increased inspiratory and expiratory effort, and 
externally audible inspiratory and expiratory ‘puffing’. At this stage, thoracic auscultation 
revealed increased audibility of breath sounds over the dorsal hemithoraces, but no adventitious 
sounds. Subjectively there was increased evidence of pleurodynia, manifested as increased 
reluctance to move, increased bruxism and occasional expiratory grunting. There were marked 
generalised fine muscle tremors. Cardiac rhythm, pulse strength, mucous membrane colour and 
capillary refill time remained unremarkable. Vaginal endoscopic examination was 
unremarkable. Ventilation perfusion mismatching and alveolar hyperventilation were 
evidenced by decreases in PaO2 (84 to 66 mmHg), SaO2 (96 to 92%) and PaCO2 (48 to 30 
mmHg). Supplemental intranasal O2 was supplied at 10-15 L/min. Given the apparent increase 
in pleurodynia, morphine (120 mg IV) and meloxicam (140 mg IV) were administered; this 
improved demeanour only marginally and did not prevent the continuing increase in heart and 
breathing rates. Clinical parameters continued to deteriorate and at 4 h post tPA instillation 
diffuse bilateral pulmonary oedema was evidenced by the onset of widespread and increasingly 
audible end inspiratory crackles and diffuse ultrasonographic ring-down artefacts present over 
the entire lungfield (Supplementary Video File 2). At this stage, ultrasonography demonstrated 
that tPA had rapidly induced partial pleural fibrinolysis, with the fibrin loculations being 
partially replaced by freely moving fluid containing hyperechoic foci. It was apparent that 
pleural fibrinolysis had reduced the restrictive effects of pleural adhesions on lung motion, 
thereby increasing lung motion during the breath cycle, and facilitating re-expansion of the 
previously collapsed ventral lung. Ultrasonography also revealed a clinically insignificant 
small volume pneumothorax and absence of pericardial effusion and haemothorax. RPE was 
suspected, although an adverse drug reaction could not be eliminated.  
Treatment of suspected RPE  
Intranasal oxygen supplementation was continued. Frusemide (500 mg IV) and hydroxyethyl 
starch (6% 130/0.4 in 0.9% saline; 1 L/h IV) were administered, and intravenous crystalloids 
discontinued. Clinical parameters continued to deteriorate for 6-8 h following tPA instillation, 
before stabilising and thereafter improving gradually. Clinical parameters and arterial blood 
gas concentrations had returned to baseline (i.e. pre-tPa instillation) levels by 12-24 h. 
Ultrasonographic examination at 18 h post tPA instillation demonstrated resolution of ring-
down artefacts, lysis of fibrin loculations, increased lung motion and re-expansion of ventral 
lung regions (Supplementary Video File 3). Intranasal O2 was discontinued after 24 h. Further 
thoracocentesis, pleural lavage and intrapleural tPA instillation was delayed for 24 h. Thoracic 
drainage performed 48 h after tPA instillation yielded 10 and 5 L pleural fluid containing 
numerous clumps of fibrin from left and right hemithoraces, respectively (Figures 1 and 2). 
Subsequent thoracocentesis (n=11) and bilateral intrapleural tPA instillation (n=3) had no 
apparent adverse effects, yielding a total of 22.5 L and 25 L, from left and right hemithoraces, 
respectively. Thoracic drains were removed after 13 and 19 days. Thereafter the mare made an 
uneventful recovery, foaled successfully and was alive 8 months after hospital discharge.  
 
Discussion 
RPE is a potentially fatal iatrogenic complication of rapid lung re-expansion following 
thoracocentesis for the treatment of pneumothorax or pleural effusion. While the 
pathophysiology of RPE remains poorly understood, it is likely multifactorial, with pulmonary 
vascular injury and increased pulmonary capillary permeability having key contributing roles 
(Genofre et al. 2003; Sherman 2003; Feller-Kopman et al. 2007; Sohara 2008). Risk factors 
for RPE in some studies include severity and duration of lung collapse, rapidity of lung re-
expansion, use of high suction pressures for thoracocentesis and the concomitant presence of 
pneumothorax and pleural effusion (Mahfood et al. 1988; Taira et al. 2014). In this case, the 
suspected RPE was clearly not a consequence of rapid drainage of pleural fluid, because fibrin 
loculations prevented effective drainage, and only small volumes of pleural fluid had been 
obtained. In contrast, we hypothesise that RPE developed because of rapid re-expansion of 
chronically collapsed lung as a result of rapid breakdown of restrictive fibrin adhesions and 
loculations following intrapleural fibrinolysis. Consistent with this possibility, ultrasonography 
indicated that pleural fibrinolysis had indeed rapidly (within 4 h) reduced the restrictive effects 
of pleural adhesions on lung motion, thereby facilitating lung re-expansion of the previously 
collapsed ventral lung regions. RPE appears to be an uncommon adverse consequence of this 
treatment, since this horse was the only one of 25 tPA treated horses that developed suspected 
RPE (Tomlinson et al. 2015). The authors are unaware of reports of RPE following intrapleural 
tPA instillation in human patients. 
There is no definitive diagnostic test for RPE. In human patients, RPE is suspected whenever 
there is sudden respiratory or haemodynamic deterioration following pleural drainage of air or 
fluid (Mahfood et al. 1988). The mare in this report met clinical criteria for human RPE, having 
at least two of the following: worsening dyspnoea, hypoxaemia, tachypnoea, hemodynamic 
instability, or a new cough lasting more than 20 min (Feller-Kopman et al. 2007). The presence 
of diffuse bilateral pulmonary oedema was confirmed by the rapid development, and 
subsequent rapid resolution, of audible inspiratory crackles and multiple ultrasonographic ring-
down artefacts present across the entire lungfields. Ultrasonographic ring-down artefact score 
is correlated with extravascular lung water content, and is sufficiently sensitive to detect 
pulmonary interstitial oedema even before it becomes clinically apparent (Jambrik et al. 2004; 
Agricola et al. 2005). Given the utility of ultrasonography for diagnosis of pulmonary oedema 
(Louvet and Bourgeois 2008), thoracic radiography and endoscopy were not considered 
necessary to confirm the presence of pulmonary oedema, and would likely have caused the 
horse further distress. Clinical examination and ultrasonography ruled out other potential 
causes of acute deterioration following attempted thoracic drainage including iatrogenic injury 
to lungs, heart, diaphragm and abdominal viscera, pneumothorax, haemothorax, and cardiac 
dysrhythmia. While an adverse reaction to tPA cannot he excluded, this appears unlikely given 
that subsequent instillation of similar doses of tPA into both pleural cavities on three occasions 
had no apparent adverse effect. While thoracocentesis and intrapleural instillation of tPA can 
exacerbate pleurodynia in human patients, increased pleurodynia alone was unlikely to have 
caused the clinical deterioration, since administration of morphine and meloxicam resulted in 
only a minor improvement in clinical parameters. More likely, as occurs in human RPE (Feller-
Kopman 2007), increased pleurodynia was a symptom of RPE, possibly due to the increased 
rate and depth of breathing occurring in response to hypoxaemia.  
As occurred in this case, clinical signs of RPE in human patients typically commence within 
1-2 h after intervention, and always within 24 h (Mahfood et al. 1988; Genofre et al. 2003; 
Taira et al. 2014). Careful patient monitoring is important during this critical time period, 
because early recognition and fast symptom-orientated treatment are necessary for survival 
(Taira et al. 2014). Treatment of symptomatic human RPE is largely supportive, including 
diuresis, supplemental oxygen, positive pressure ventilation, morphine and glucocorticoids 
(Light 1995; Taira et al. 2014). The mare in this report received a diuretic, supplemental oxygen 
and morphine. Intravenous crystalloid therapy was discontinued because volume overload may 
exacerbate pulmonary oedema and increase patient mortality, particularly when pulmonary 
vascular permeability is increased (Calfee and Matthay 2007; Lyons 2008). Hydroxyethyl 
starch was administered because it can attenuate pulmonary vascular permeability and improve 
haemodynamics and cardiac output without worsening pulmonary oedema and pulmonary 
mechanics in human acute respiratory distress syndrome (Huang et al. 2009). While morphine 
was administered largely for its analgesic properties, it can aid treatment of human cardiogenic 
pulmonary oedema by reducing anxiety, improving breathing pattern and reducing venous tone 
and peripheral vascular resistance via central sympatholysis (Robin et al. 1973). Other reported 
treatments for pulmonary oedema not used in this case include acepromazine, inhaled β2-
agonist bronchodilators, inhaled frusemide, nebulization of 20% alcohol to reduce surface 
tension of oedema fluid and foam formation, and suction of accumulated fluid from proximal 
airways (Atabai et al. 2002; Senior 2005; Dunkel 2006). Recommended protocols to minimise 
occurrence of human RPE include use of small-diameter thoracic drains and avoidance of 
suction pressures exceeding 10-20 cmH2O, although adherence to these protocols does not 
eliminate the risk of RPE (Light 1995; Feller-Kopman et al. 2007; Taira et al. 2014).  
In summary, this case suggests that RPE can occur as an iatrogenic complication of rapid lung 
re-expansion following intrapleural tPA administration in horses with fibrinous pleural 
effusion. Clinicians should consider this complication when a horse undergoing this treatment 
has sudden worsening of dyspnoea, hypoxaemia, tachypnoea, hemodynamic instability and/or 
sudden onset coughing.  
 
Figures 
Figure 1; Pleural fluid collected at 48 h after tPA instillation, showing numerous clumps of 
fibrin consistent with pleural fibrinolysis.  
Figure 2; Close up view of fibrin clump.  
 
Supplementary Video Files 
Video 1; Ultrasonogram of the left ventral hemithorax recorded on Day 2 of hospitalisation 
showing organising fibrinous pleuropneumonia. The extensive fibrinous pleural loculations 
and inter-pleural adhesions are restricting lung expansion, and consequently there is little 
movement of the lung in relation to the parietal pleura. There is also marked collapse of the 
ventral lung. Dorsal to left of image. Scale = cm.  
Video 2; Thoracic ultrasonogram from a horse with cardiogenic pulmonary oedema illustrating 
multiple ring-down artefacts, similar to those identified in the case reported herein. Please note 
that this image is included for illustrative purposes only and is not from the subject of this case 
report. Dorsal to left of image. Scale = cm. 
Video 3; Ultrasonogram of the left ventral hemithorax recorded 18 h after tPA instillation. 
There is clear evidence of pleural fibrinolysis, with a marked reduction in fibrin loculations 
and an accompanying increase in freely moving fluid containing hyperechoic foci. The 
pericardio-diaphragmatic ligament is now evident. The previously restricted and adherent lung 
is now moving more freely in relation to the parietal pleura during the breath cycle. There is 
also marked reduction in the volume of collapsed lung indicating pulmonary re-inflation. 
Dorsal to left of image. Scale = cm. 
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